IGF-1, Nutrition, and Fasting: What Diet Actually Does to Your Levels

Insulin-like growth factor 1 (IGF-1, also called somatomedin C) is a peptide hormone made mostly in the liver in response to growth hormone (GH). It is the standard blood test used to estimate average GH exposure over the preceding days to weeks, and it is the lab most often ordered before and during sermorelin, ipamorelin/CJC-1295, tesamorelin, or MK-677 (ibutamoren) protocols. IGF-1 is not itself a drug; it is a biomarker, and its value moves for reasons that have nothing to do with the pituitary or a peptide dose.

The useful question when you get an IGF-1 result is not "is this number good or bad" but "was this number drawn under conditions that make it interpretable." Caloric intake and dietary protein are the two strongest short-term nutritional influences on circulating IGF-1, and a fasting or under-fed state can push IGF-1 down enough to look like growth hormone deficiency even when GH secretion is normal or elevated. This is well established physiology (the liver becomes transiently resistant to GH under low insulin and low amino-acid conditions), but the exact percentage change reported for any single study should be treated as a ballpark from that specific population, not a number you can apply to your own lab report.

What is established, what is plausible, and what is not

Established: Growth hormone signaling requires an adequately fed liver. Caloric restriction and low protein intake reduce hepatic responsiveness to GH through a state generally called acquired GH resistance, so IGF-1 can fall even while GH pulses are normal or increased. This mechanism has been described in the endocrinology literature going back decades and is not controversial.

Plausible but not settled for an individual patient: The idea that a specific IGF-1 target (for example, a particular number in the 150 to 250 ng/mL range) is optimal for longevity or body composition in adults not being treated for GH deficiency. This target is used by some longevity-medicine practitioners as a matter of clinical judgment, not because a professional society has endorsed a specific optimal number for healthy adults.

Not established: That deliberately lowering IGF-1 through diet extends human lifespan. Caloric restriction studies in humans have reported reduced IGF-1 alongside other biomarker changes, and rodent studies link methionine restriction to lifespan extension, but a causal, dose-specific human longevity benefit from IGF-1 suppression has not been shown in controlled human trials.

Why food and fasting move IGF-1 independent of the pituitary

IGF-1 synthesis in the liver depends on two permissive conditions: adequate circulating insulin and adequate amino acid substrate (particularly branched-chain amino acids). When either is scarce, as happens during fasting, severe caloric restriction, or chronic low-protein eating, the liver down-regulates its response to GH at a post-receptor signaling step. GH secretion from the pituitary is not impaired, and in some fasting studies GH secretion actually rises, while IGF-1 still falls. This dissociation, sometimes called nutritionally acquired GH resistance, is the central reason an IGF-1 drawn during an active diet change is difficult to interpret on its own.

Practically, this means a healthy person mid-fast or several weeks into an aggressive calorie cut can produce an IGF-1 result that looks like adult GH deficiency, and a person eating a high-protein, calorie-adequate diet can produce a result that looks artificially high relative to their true GH output. Neither extreme reflects the pituitary-GH axis by itself.

Fasting and caloric restriction: direction and rough magnitude

Short fasts of several days have been reported in the physiology literature to lower IGF-1 substantially, in some studies by roughly half, within about a week, even when GH secretion increases over the same period. Longer, moderate caloric restriction studies in humans (including large randomized trials of sustained calorie restriction in non-obese adults) have reported smaller but sustained reductions in IGF-1, on the order of 20 to 30 percent, over many months to years of restriction compared with ad-lib eating.

These figures come from specific study populations under specific conditions and should not be read as a formula that predicts your own percentage change. If you are considering these numbers for a clinical decision, the underlying papers should be pulled and checked against your situation before you rely on them.

Recovery is not immediate. Refeeding after a prolonged fast raises IGF-1, but published refeeding studies suggest it can take on the order of a few weeks for IGF-1 to return to a pre-fast baseline. A reasonable practical rule, pending verification against your own lab's guidance, is to avoid drawing an IGF-1 within roughly three weeks of ending a multi-day fast or a very low-calorie protocol if you want a value that reflects your usual state.

Protein intake: the strongest single dietary lever

Across multiple feeding studies, dietary protein has a clearer dose-response relationship with IGF-1 than any other macronutrient, because amino acids are both raw material for liver protein synthesis and direct signals for IGF-1 gene expression. Reducing protein well below typical intake (into the range of roughly 0.4 g/kg/day) has been shown in controlled feeding studies to lower IGF-1 meaningfully over a few weeks without any change in GH pulse frequency or amplitude, again pointing to a liver-level effect rather than a pituitary effect. Increasing protein above a maintenance level toward the range recommended for resistance-trained adults has been associated with higher IGF-1 in controlled comparisons.

Cross-sectional studies comparing vegan and omnivore diets at similar calorie intakes consistently find lower IGF-1 in the vegan group, an effect generally attributed to lower total protein and lower intake of specific amino acids like leucine rather than to any particular plant compound. A vegan diet that reaches a protein target through legumes, soy foods, and supplementation will suppress IGF-1 far less than a low-protein vegan pattern.

Methionine restriction specifically has drawn attention because rodent studies link large reductions in dietary methionine to extended lifespan and lower IGF-1. Whether this applies to humans at achievable levels of restriction is genuinely uncertain, and epidemiological comparisons between vegans and omnivores cannot cleanly separate methionine's effect from the effect of lower total protein.

A decision framework: is this IGF-1 result nutritional, or is it the GH axis?

Use this sequence before treating any single IGF-1 value as diagnostic of GH status.

Step 1: Check the eating pattern in the two weeks before the draw.

• Any fast longer than about 18 hours in the 72 hours before the draw, or any period of aggressive calorie restriction in the two weeks before the draw, makes the result unreliable for GH axis assessment. Label the result "nutritionally confounded" and repeat under stable conditions rather than acting on it.
• A standard 8 to 12 hour overnight fast for the blood draw itself is normal and expected; this is different from a multi-day fast and does not invalidate the result.

Step 2: Check protein intake, not just calories.

• Protein intake sustained below roughly 0.8 g/kg/day in the week before the draw is a plausible explanation for a low result on its own, independent of GH secretion.
• Protein intake sustained above roughly 1.6 g/kg/day can push IGF-1 toward the upper part of the normal range even without a peptide or GH drug on board.

Step 3: Rule out non-nutritional suppressors before assuming a diet problem or a GH problem.

• Hypothyroidism (even subclinical) reduces hepatic GH receptor expression and can lower IGF-1; check TSH and free T4.
• Poorly controlled diabetes and significant liver disease also suppress IGF-1 independent of GH output.

Step 4: Only after steps 1 to 3 are clear, treat the value as informative about the GH axis or a peptide's effect.

• A low IGF-1 that persists after confirmed stable eating, adequate protein, normal thyroid function, and no liver or diabetes explanation is the point at which a GH stimulation test (not a repeat IGF-1 alone) becomes the appropriate next step, in consultation with the prescribing clinician.
• On a peptide protocol, a blunted IGF-1 response with confirmed inadequate protein or an active calorie deficit should prompt a nutrition fix before a dose increase.

What this framework does not do: it does not replace clinical judgment, and it does not set a dosing decision. It is a way to avoid the most common error in this population, which is treating a diet-suppressed or diet-elevated IGF-1 as if it were purely a GH axis measurement.

Reference ranges, and why "normal" is not the same as "optimal"

Commercial lab reference ranges for IGF-1 are age- and sex-stratified because IGF-1 peaks in adolescence and declines through adulthood. These ranges describe the central range of a tested population; they are not a claim about what level is best for an individual. A person in the lowest part of the normal range for their age can still be statistically "normal" while having symptoms sometimes associated with relatively low IGF-1, such as fatigue or reduced lean mass, that a clinician managing a GH axis condition would take seriously.

The Endocrine Society's clinical practice guideline on adult GH deficiency recommends that, in patients being treated for confirmed GH deficiency, IGF-1 should be brought into the normal range for age and sex, and many clinicians aim for the upper half of that range rather than the low end. This is a guideline recommendation for a specific, diagnosed patient population, not a general recommendation for healthy adults optimizing for longevity, and it should not be extended to that broader population without qualification.

Separately, prospective cohort studies have associated the upper end of the IGF-1 distribution with a modestly higher relative risk of certain hormone-sensitive cancers, including breast and prostate cancer. This is observational, cohort-level evidence, not a demonstrated causal mechanism in an individual, but it is a reasonable part of why most clinicians do not deliberately target the very top of the reference range without a clear clinical indication. Anyone relying on the specific magnitude of that risk association for a treatment decision should verify the exact figure against the primary study rather than relying on a secondhand summary.

GH peptide therapy and nutrition together

Sermorelin and ipamorelin combined with CJC-1295 are GH secretagogues used off-label for adults seeking improvements in body composition, recovery, or age-related GH decline; this is not an FDA-approved indication, and dosing and monitoring should follow the prescribing clinician. Tesamorelin (brand name Egrifta) is FDA-approved specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; its label documents IGF-1 increases in that approved population, and the exact magnitude reported on the label should be checked directly against the current label rather than assumed from a secondary source (see FDA label reference below).

Regardless of which peptide is used, the mechanism runs through the same liver step described above: the peptide increases GH pulsing, but the liver still needs adequate insulin and amino acid substrate to convert that GH signal into IGF-1. A patient who is under-eating protein or running a calorie deficit while on a peptide protocol may see a smaller IGF-1 rise than expected, and that blunted result is not necessarily evidence that the peptide dose is too low. Confirming protein intake of roughly 1.2 g/kg/day or more, and stable (non-fasting) eating for at least a couple of weeks, is a reasonable first check before adjusting a peptide dose based on a lab result.

Preparing for a lab draw you can actually trust

• Draw the sample after at least two weeks of stable, typical eating, not mid-diet-cut and not during an extended fasting protocol.
• Keep protein intake at your usual level for at least a week before the draw.
• A standard overnight fast (roughly 8 to 12 hours) the morning of the draw is normal lab practice and is not the same as a multi-day fast.
• If you are on a peptide or GH protocol, follow your prescribing clinician's specific timing instructions relative to your last dose; protocols vary and there is no single correct timing for every patient.
• Avoid drawing within about two weeks of an acute illness, since infection and inflammation can suppress IGF-1 acutely and independent of nutrition or GH status.

When to escalate beyond diet and lab timing

A single low IGF-1 drawn during a calorie deficit or a fast does not, by itself, justify pituitary imaging or a GH stimulation test. It justifies a repeat draw under stable conditions. Escalation to formal GH stimulation testing (such as an insulin tolerance test or glucagon stimulation test) is appropriate when a low IGF-1 persists after nutrition, thyroid status, glucose control, and liver function have been checked and stable eating has been confirmed for several weeks. That decision, and any GH replacement decision that follows it, belongs with an endocrinologist or the prescribing clinician managing the case, not with a single at-home interpretation of a lab number.